Letters
Avastin versus Lucentis
Approve bevacizumab for use in eye disease in cash strapped times
BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e4806 (Published 23 July 2012) Cite this as: BMJ 2012;345:e4806
- Ilias Georgalas, consultant ophthalmic surgeon1,
- Chrysanthi Koutsandrea, consultant vitreoretinal surgeon1
- 1Department of Ophthalmology, University of Athens, 11527 Athens, Greece
- igeorgalas{at}yahoo.com
We agree with Godlee that the “miracle” of anti-VEGF (vascular endothelial growth factor) treatment has been overshadowed by the bevacizumab (Avastin) versus ranibuzimab (Lucentis) dispute.1
However, in our opinion, the anti-VEGF treatment versus no treatment debate is even more important. During this economic crisis, many of our patients with …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.